Table 1.

Outcomes of Patients With Lung Cancer Without SARS-CoV-2 Infection Treated at the Zhongnan Hospital of Wuhan University

	RT n = 28, n (%)	CT and Immunotherapy n = 206, n (%)	TKI n = 42, n (%)	Total n = 276, n (%)
Treatment on schedule	0	14 (6.8)	42 (100.0)	56 (20.3)
Switching from intravenous CT to an oral therapy	0	23 (11.2)	0	23 (8.3)
Treatment interruption	28 (100.0)	169 (82.0)	0	197 (71.4)
Reports of suspicious symptoms associated with progression	3/28 (10.7)	44/169 (26.0)	NA	50/197 (25.4)

CT, chemotherapy; NA, not applicable; RT, radiotherapy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TKI, tyrosine kinase inhibitor.